Fax: (011) 39 0516364037
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma
Article first published online: 2 OCT 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 9, pages 2496–2503, 1 November 2008
How to Cite
Derenzini, E., Musuraca, G., Fanti, S., Stefoni, V., Tani, M., Alinari, L., Venturini, F., Gandolfi, L., Baccarani, M. and Zinzani, P. L. (2008), Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer, 113: 2496–2503. doi: 10.1002/cncr.23861
- Issue published online: 17 OCT 2008
- Article first published online: 2 OCT 2008
- Manuscript Accepted: 16 JUN 2008
- Manuscript Revised: 9 JUN 2008
- Manuscript Received: 17 MAR 2008
- diffuse large B-cell lymphoma;
- follicular lymphoma;
- autologous stem cell transplantation;
- positron emission tomography;
- progression-free survival;
- secondary age-adjusted International Prognostic Index
Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT). The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy.
Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included. All patients were evaluated by PET after 1 to 3 courses of IEV chemotherapy before ASCT, and all patients received a conditioning regimen of combined carmustine, etoposide, cytosine arabinoside, and melphalan. The prognostic impact of pretransplantation PET, sAA-IPI score, histology, and previous response to first-line chemotherapy was evaluated by univariate and multivariate analyses.
Seventy-two of 75 patients underwent ASCT. In a univariate analysis for progression-free survival (PFS) and overall survival (OS), a significant association was observed with pretransplantation PET (PFS, P < .00001; OS, P < .01) and previous first-line response (PFS, P = .02; OS, P = .04). In the multivariate framework, pretransplantation PET was identified as the only independent prognostic factor (PFS, P < .001; OS, P = .01).
The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT. Cancer 2008. © 2008 American Cancer Society.